Stock Trading Canary

United States · SEC Form 4 · Snapshot date: 2026-10-18 · Built: 2026-10-18 · 中文

← United States · Coverage record

US · SEC FORM 4

Relay Therapeutics, Inc.

RLAY · Nasdaq · CIK 0001812364 · Healthcare · Biotechnology

INSIDER SIGNAL

No active buy signal

0 qualifying P purchase groups
in the current 180-day scoring window

32 Form 4 transaction lines observed in the same window
26 sales · 6 option, withholding, award, gift or other lines

Last qualifying purchase2020-07-20 · Patel Sanjiv · $500.0K

WHY NO ACTIVE SIGNAL?

Purchase activityNone
Recent buyingNone
Recent salesHigh
Buy signal statusInactive
Score anatomy

No score is calculated because there is no qualifying purchase in the active window. Unavailable inputs are not treated as zero or as a bearish signal.

ClusterNot calculated
Purchase sizeNot calculated
RoleNot calculated
RecencyNot calculated
ConvictionNot calculated

Why is there no score?

  • No qualifying open-market purchase supplies cluster, size, role, recency or conviction inputs.
  • Sales and other Form 4 activity remain visible as context and do not create a negative score.

Sales and other Form 4 activity are shown separately and do not create a negative buy signal. Absence of buying is not scored as bearish.

Insider activity timeline

Owner lanes show the latest 180 days. Symbol shape identifies the transaction type; sales remain context only.

AprMayJunJulAugSepOct
Catinazzo ThomasChief Financial Officer
▼▼○▼▼▼▼▼▼
Bergstrom Donald APresident, R&D
▼○▼▼▼▼
Patel SanjivPresident and CEO
○▼▼▼▼
Rahmer PeterSee remarks
▼○▼▼▼
SB INVESTMENT ADVISERS (UK) LTD; SOFTBANK VISION FUND (AIV M2) L.P.; SVF Pauling (Cayman) LtdTenPercentOwner
▼
● Purchase▼ Sale○ Other

—

Purchase breadth, concentration & cluster buying

These modules activate when qualifying purchases enter the 180-day research window.

SIGNAL HISTORY

No recorded active-signal snapshot

Scores are archived only when the company qualifies for a published US buy-signal snapshot. Last qualifying purchase: 2020-07-20 · Patel Sanjiv.

Recent Form 4 activity

0Purchases
41Sales
9Other Form 4 lines
32SEC filings · 365 days
BUYING0 qualifying P line(s) · 180 days
SELLING26 sale line(s) · context only
OTHER6 exercise / withholding / award / gift / other lines
10b5-1 / PLANNEDNot assessed

P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.

Market context

Market context has not been captured for this ticker yet. The daily market-context job processes the US universe in rotating batches.

Short interest

Short interest is external context reported to FINRA by broker-dealers. It does not affect the Insider Signal.

Shares short
46,746,942
Previous report
44,487,428
Avg daily volume
3,712,736
Days to cover
12.6

FINRA settlement date: 2026-09-30 · Captured 2026-10-12 · FINRA equity short interest ↗. A share count, published about a week after each of two settlement dates a month; not a percentage of shares outstanding.

Historical equity purchases

Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.

Transaction dateReporting ownerTypeSecuritySharesAvg. priceApprox. valueSource
2020-07-20Rubin JamiPurchase (P)Common Stock25,000USD 20.00USD 500,000SEC filing ↗
2020-07-20Patel SanjivPurchase (P)Common Stock25,000USD 20.00USD 500,000SEC filing ↗
2020-07-20Murcko MarkPurchase (P)Common Stock25,000USD 20.00USD 500,000SEC filing ↗
2020-07-20INGRAM DOUGLAS SPurchase (P)Common Stock25,000USD 20.00USD 500,000SEC filing ↗
2020-07-20Adams BrianPurchase (P)Common Stock10,000USD 20.00USD 200,000SEC filing ↗

Form 4 evidence

50 transaction lines in the latest 365-day window; 385 in local history.

DateOwnerTypeSecuritySharesAvg. priceApprox. valueSource
2026-10-07Patel SanjivSale (S)Common Stock48,199USD 18.10USD 872,402SEC filing ↗
2026-10-06Catinazzo ThomasSale (S)Common Stock17,717USD 18.59USD 329,322SEC filing ↗
2026-09-08Patel SanjivSale (S)Common Stock48,199USD 18.94USD 912,889SEC filing ↗
Show recent Form 4 evidence (30 grouped rows)
DateOwnerTypeSecuritySharesAvg. priceApprox. valueSource
2026-10-07Patel SanjivSale (S)Common Stock48,199USD 18.10USD 872,402SEC filing ↗
2026-10-06Catinazzo ThomasSale (S)Common Stock17,717USD 18.59USD 329,322SEC filing ↗
2026-09-08Patel SanjivSale (S)Common Stock48,199USD 18.94USD 912,889SEC filing ↗
2026-09-08Catinazzo ThomasSale (S)Common Stock17,717USD 18.94USD 335,560SEC filing ↗
2026-09-08Bergstrom Donald ASale (S)Common Stock8,530USD 18.97USD 161,814SEC filing ↗
2026-08-26Rahmer PeterSale (S)Common Stock4,508USD 20.03USD 90,295SEC filing ↗
2026-08-25SB INVESTMENT ADVISERS (UK) LTD; SOFTBANK VISION FUND (AIV M2) L.P.; SVF Pauling (Cayman) LtdSale (S)Common Stock6,000,000USD 19.40USD 116,400,000SEC filing ↗
2026-08-17Patel SanjivSale (S)Common Stock48,199USD 20.33USD 979,886SEC filing ↗
2026-08-14Catinazzo ThomasSale (S)Common Stock17,717USD 19.74USD 349,734SEC filing ↗
2026-07-28Rahmer PeterSale (S)Common Stock748USD 18.61USD 13,920SEC filing ↗
2026-07-28Catinazzo ThomasSale (S)Common Stock1,459USD 18.61USD 27,152SEC filing ↗
2026-07-28Bergstrom Donald ASale (S)Common Stock2,237USD 18.61USD 41,631SEC filing ↗
2026-07-07Patel SanjivSale (S)Common Stock48,199USD 19.58USD 943,736SEC filing ↗
2026-07-06Catinazzo ThomasSale (S)Common Stock17,717USD 18.69USD 331,131SEC filing ↗
2026-07-06Bergstrom Donald ASale (S)Common Stock8,660USD 18.71USD 162,029SEC filing ↗
2026-06-30Patel SanjivAward / grant (A)Common Stock3,056USD 6.95USD 21,239SEC filing ↗
2026-06-30Rahmer PeterSale (S)Common Stock50,000USD 19.09USD 954,500SEC filing ↗
2026-06-30Rahmer PeterAward / grant (A)Common Stock3,056USD 6.95USD 21,239SEC filing ↗
2026-06-22Catinazzo ThomasSale (S)Common Stock187,163USD 16.97USD 3,176,865SEC filing ↗
2026-06-22Catinazzo ThomasOption exercise / conversion (M)Common Stock169,446USD 4.93USD 834,669SEC filing ↗
2026-06-22Bergstrom Donald ASale (S)Common Stock93,456USD 16.94USD 1,583,145SEC filing ↗
2026-06-22Bergstrom Donald AOption exercise / conversion (M)Common Stock93,456USD 4.12USD 385,039SEC filing ↗
2026-05-14Catinazzo ThomasSale (S)Common Stock17,717USD 12.86USD 227,841SEC filing ↗
2026-04-28Rahmer PeterSale (S)Common Stock753USD 14.79USD 11,137SEC filing ↗
2026-04-28Catinazzo ThomasSale (S)Common Stock972USD 14.79USD 14,376SEC filing ↗
2026-04-28Bergstrom Donald ASale (S)Common Stock1,490USD 14.79USD 22,037SEC filing ↗
2026-04-09Catinazzo ThomasSale (S)Common Stock1,800USD 15.00USD 27,000SEC filing ↗
2026-04-09Catinazzo ThomasOption exercise / conversion (M)Common Stock1,800USD 5.22USD 9,396SEC filing ↗
2026-04-07Catinazzo ThomasSale (S)Common Stock17,717USD 13.01USD 230,498SEC filing ↗
2026-03-09Catinazzo ThomasSale (S)Common Stock17,717USD 10.06USD 178,233SEC filing ↗

Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.

Snapshot & identity

Snapshot date2026-10-18
Ranking versionUS-v1.2
Data qualityPASS ELIGIBLE · —
TickerRLAY
CIK0001812364
SectorHealthcare
IndustryBiotechnology Yahoo Finance
SEC SIC2836 Biological Products, (No Diagnostic Substances)
ExchangeNasdaq

Data coverage

Local Form 4 history385 transaction lines from 2020-07-20 to 2026-10-07
5 P purchase lines · 273 S sale lines · 107 other lines
SEC company submissionsOpen SEC filings ↗

Local ledger as of 2026-10-18. Mapping status is an audit field and does not erase SEC filing evidence.